Eli Lilly & Co. (LLY) Reports New Verzenio Phase 3 monarchE Trial Data Published in the Annals of Oncology
Go back to Eli Lilly & Co. (LLY) Reports New Verzenio Phase 3 monarchE Trial Data Published in the Annals of Oncology| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1137.82 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1137.82 | 52 Week High | $88.16 | |||
| Open | $1137.82 | 52 Week Low | $67.88 | |||
| Day High | $1137.82 | P/E | 263.38 | |||
| Day Low | $1137.82 | EPS | $4.32 | |||
| Volume | 4,914 | |||||
